Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Clinical Trials

Cardiology

SRSD107

More Like This

Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

PR Newswire associated0

ISTH announces launch of new global education initiative in factor XI/XIa inhibition

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR Newswire associated0

Seragon Completes Pre-Clinical Study of Aging Intervention Candidate SRN-901

Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

Exciting Progress | Gritgen Therapeutics Completed Patients Enrollment in China’s First Gene Therapy Investigator-Initiated Trial for Hemophilia A and also Achieved the First Patient Dosed in China Phase I Trial in Patients with Severe Hemophilia A